Canada-Nigeria Mpox Partnership (CAMP)

About the study

The Canada-Nigeria Mpox Partnership (CAMP) is a multinational, multidisciplinary network that has brought together 68 researchers from Canada, Nigeria, US and UK to collaborate on a suite of projects looking at the various aspects of the 2022 mpox epidemic. The project has three main objectives:

 

Objective 1: To characterize and compare mpox transmission dynamics and serologic histories across epidemic contexts

Projects include:

• Mpox Prospective Observational Cohort Study (MPOCS)
• Determining the extent to which environmental surfaces and/or air in proximity to people affect transmission
• Prevalence of asymptomatic and subclinical infection
• Elucidate differential mpox transmission dynamics through mathematical modelling

Objective 2: To evaluate the role of the antiviral tecovirimat in the treatment of human mpox infection

Projects include:

• Placebo-controlled randomized trial of tecovirimat in non-hospitalized patients with Mpox: Canadian Feasibility Study (PLATINUM-CAN)

Objective 3: To evaluate the role of Imvamune® vaccine in the prevention of human mpox infection

Projects include:

• Estimating vaccine effectiveness
• Comparing population-level impact of vaccine strategies

 

More information

Launch announcement from EPIC

CAMP-Nigeria webpage

 

Funding

This project was funded by CIHR, IDRC, PHAC, EPIC.

 

Related Publications

Protocol for the Mpox Prospective Observational Cohort Study (MPOCS) Among Individuals with mpox in Canada

Longitudinal Analysis of Mpox Virus DNA Detectability From Multiple Specimen Types During Acute Illness: A Cohort Study

Impact of interventions on mpox transmission during the 2022 outbreak in Canada: a mathematical modeling study of three different cities.

Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial

Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study

Environmental Testing of Surfaces in the Room of a Patient With Mpox

Environmental Surface Contamination with Monkeypox Virus in the Ambulatory Setting in Toronto, Canada

Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials

Monkeypox virus transcriptional profiles and host responses in skin lesion swabs among individuals with HIV

Monkeypox virus shedding despite tecovirimat treatment in a cohort in Toronto, Canada